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Pharmacogenetics is the study of genomic-guided individualized drug prescription
that plays an important role in preventing the severe adverse effects of drugs, decreasing
the time and cost of therapeutic choices, and directing healthcare professionals to choose
medications that are effective and safe. It is noteworthy that this approach becomes
highly beneficial in patients suffering from chronic diseases or disorders, since these
conditions may require multiple and long term pharmacological therapies, as in children
with autism spectrum disorder (ASD). However, public acceptance is a major challenge
when implementation of pharmacogenetics merges into clinical practice. The purpose of
this study is a) to investigate, among small cohort group of children with ASD, several
genetic variants of enzymes that influence the metabolism of commonly prescribed drugs
to treat ASD and b) to inspect the knowledge of, attitude towards and future expectations
with regards to pharmacogenetics among parents of children with ASD. A group of 15
school-aged participants with ASD were recruited for the study. Approximately 5 ml of
venous blood was drawn for each participant to analyze the genotype of enzymes
implicated in drug metabolism via pharmacogenetics testing. Thereafter, the parents of
these children attended a training session to help them gain a better understanding of the
pharmacogenetics results depicted in the drug panel results. A pre-training and posttraining survey was conducted to assess the knowledge of, attitude towards and future
expectations of pharmacogenetics among the children’s parents.
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Chapter One: Introduction
The number of diagnoses of autism spectrum disorder (ASD) is escalating. The
CDC reports that one in every 68 children is diagnosed with ASD in the United States.
This fact is indicative of the increased demand for pharmacological treatment options
(Bowker, D'Angelo, Hicks, & Wells, 2011). The concomitant use of multiple therapeutic
modalities to treat ASD creates uncertainty about the efficacy of each method separately.
Several pharmacological therapies are used for different behaviors associated with ASD;
however their efficacy is not ensured and there may be severe adverse effects in some
patients (Bowker et al., 2011; Zane, Davis, & Rosswurm, 2008). This emphasizes the
need to seek further testing that will help physicians make more targeted and effective
pharmacological choices for the patients of children with ASD in order to avoid adverse
effects of the prescribed medications (Bowker et al., 2011; Zane et al., 2008).
Pharmacogenetics is the study of the genes that affect the response of medications
in the body. Most of the genes that are commonly tested play an important role in
regulating the family of enzymes responsible for the metabolism of drugs.
Pharmacogenetics testing is highly promising in the field of medicine in order to prevent
the occurrence of adverse effects of medications and giving insight into appropriate,
personally-tailored dosage guidelines to assure drug safety and efficacy (Wolf, Smith, &
Smith, 2000),(Ensom et al., 2001), (McCarthy, 2001). However, public acceptance is a
major challenge when the implementation of pharmacogenetics merges into clinical
practice. Therefore, educating the general population about the importance of
pharmacogenetics and measuring beliefs and expectations is highly significant in
successfully applying this approach in clinical settings.
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Chapter Two: Literature Review
Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD) is a neurodevelopmental disability
characterized by restricted interests, repetitive behaviors and deficits in communication
and social reciprocity skills (White, Keonig, & Scahill, 2007). Due to the prevalence of
children identified with ASD (1 in 68 children), there is a need for interventions targeting
the specific characteristics children and adolescents with ASD display (Center for
Disease Control and Prevention, 2014).
Characteristics of Autism Spectrum Disorder
According to the Diagnostic and Statistical Manual of Mental Disorders (DSMV), there are five factors that make up the diagnostic criteria for ASD. The first feature
includes deficits, which persist over time, in social communication and social interaction.
These deficits can include, but are not limited to, abnormal social approach, failure to
grasp the pragmatics of normal conversation, failure to start or participate in social
interactions, abnormal eye contact and body language, failure to develop and maintain
social relationships, difficulties initiating or maintaining friendships, and a lack of
interest in peers. The second factor includes restricted and repetitive behaviors and
interests. Examples of this type of behavior include, but are not limited to, repetitive
speech, insistence on adhering to routines, highly restricted perseverative interests with
an abnormal intensity, and unusual sensory interests. The third factor says that the
symptoms must be present in the early developmental period. The fourth factor says that
the symptoms cause clinically significant impairment in certain areas of functioning. The
final factor says that the symptoms are not better explained by another disability.
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Pharmacological treatment of ASD
Medications are one of the multiple interventions used to treat ASD. The
concomitant use of multiple therapies to treat ASD is common due to the comorbidity
nature of the disease; thus detecting the efficacy of specific treatments is further
complicated (Bowker et al., 2011; Zane et al., 2008). However, medications that are used
to treat comorbidities associated with ASD, rather than the main symptoms of the
disorder, have been reported to be one of the most frequently discontinued treatment
methods (Bowker et al., 2011; McPheeters et al., 2011). Therefore, the increasing
demands on pursuing pharmacological choices, the lack of knowledge regarding the
efficacy of medications and the alarming adverse effects of some of the drugs, coupled
with the high cost of these modalities, prompts the need for further investigation in the
field (Bowker et al., 2011; Zane et al., 2008).
Current research regarding the most commonly prescribed medications used in the
treatment of ASD addressed the following classes of drugs: antipsychotics, antidepressants and anti-ADHD agents (McPheeters et al., 2011). Clinical use of these
medications improves challenging behaviors (irritability, aggression and self-injurious
behavior), repetitive behavior and hyperactivity respectively. Although antipsychotics,
particularly aripiprazole and risperidone, have been approved to be efficacious, adverse
effects were observed when using these agents, as 30% of patients using aripiprazole were
susceptible to weight gain. The adverse effects of atypical antipsychotics manifested by
weight gain, sedation and extrapyramidal symptoms (McPheeters et al., 2011; Stachnik &
Gabay, 2010). Two other common SSRI (a class of antidepressants) medications citalopram and fluoxetine – are used to treat individuals with ASD having specific
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problem behaviors associated with the condition. For example, fluoxetine improves
repetitive behavior and citalopram ameliorates challenging behavior.
Another class of medications that was used by 30-85% of children with ASD is
anti-ADHD, these neurostimulant medications were prescribed to provide a short-term
relief for symptoms of hyperactivity and impulsivity (Dalsgaard, Nielsen, & Simonsen,
2013; McPheeters et al., 2011). Regardless of the beneficial effects of medications used to
treat (ASD), close monitoring is required as they may cause serious adverse effects
because of the long term use of these medications (McPheeters et al., 2011).
Having expectations of the possibility to develop potential adverse effects of the
drugs, can protect the patients from being predisposed to adverse effects that can be
avoided. That critical goal in addition to saving money and giving the time for other
therapeutic choices to be prescribed, can be accomplished by requesting a
pharmacogenetics test (Bowker et al., 2011; Wolf et al., 2000; Zane et al., 2008).

Pharmacogenetics (PGx)
What is Pharmacogenetics?
Pharmacogenetics (PGx) is the study of genes that affect the response of the
medications in the body. In some literature pharmacogenetics is used interchangeably
with pharmacogenomics; however, other literature defined pharmacogenomics as the
study of the interaction effects in between genes (Zhang, Bruce, Hayden, & Rieder,
2014). Wolf et al., 2000divided the study of PGx into two aspects:
 The study of genes associated with specific diseases that can be targeted by
medications
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The study of genetic variability that can alter drug response

Medications demonstrate their actions on the body by working at three levels: the
enzymes metabolizing the drug, the signaling pathway, and the receptor on the targeted
tissues (Ensom et al., 2001). Most of the identified genetic variation is a result of single
nucleotide polymorphism SNPs that change the coding for a group of enzymes implicated
in metabolizing medications (Ensom et al., 2001). The outcome of these SNPs may range
from delayed response, increased toxicity, extended effect, adverse reaction or drug-drug
interactions (Wolf et al., 2000). Thus, DNA analyzed by the pharmacogenetics testing
would provide an individualized information about the efficacy and safety of the
prescribed medications (McCarthy, 2001).
Beneficial Role of Pharmacogenetics
One of the studies indicated that 1 in 15 hospital admissions is related to side
effects of drugs (Wolf et. al., 2000); whereas among children, adverse effects count for 24% of hospital admissions and 3% of out-patient visits (Zhang et al., 2014). Therefore,
being knowledgeable of the personalized adverse effects prospectively, by detecting the
genetic coding of enzymes responsible for the metabolism of the prescribed drugs, would
reduce the cost, time, and harmful events (Bowker et al., 2011; Zane et al., 2008).
Many patients are deprived from pharmacological choices because the standard
dose of this medication may accumulate in their body leading to drug related toxicity.
The situation becomes even more critical when the pharmacological choices are
lifesaving as in oncology patients (Drew, 2016). Pharmacogenetics testing enables
physicians to bypass all these obstacles by establishing a constant “personal
pharmacogenetics profile”. This profile can provide recommendations of the type,
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dosing, and alternative of the drugs that may be prescribed during the patient’s life time;
consequently, healthcare providers can make their decisions based on the genetic
information of the patient (Wolf et al., 2000).
Knowledge and Attitude towards Pharmacogenetics
The future of pharmacogenetics is highly promising; nonetheless, public
acceptance is still the cornerstone of pharmacogenetics’ prosperity (Innocenti, Iyer, &
Ratain, 2000; Zhang et al., 2014). Research has shown that people’s enthusiasm about
pharmacogenetics varies between the general population and those who are suffering
chronic diseases (Zhang et al., 2014). Adding to that, the baseline understanding of
pharmacogenetics and health condition had a significant effect on the individual’s level
of comfort to perform a pharmacogenetics testing (Innocenti et al., 2000). It is
noteworthy to mention that even those that showed interest in PGx testing, after testing,
they are often not compliant with the test results (Zhang et al., 2014). In other words, they
would take the medication regardless of the fact that it can cause serious side effects or
even if the drug is contraindicated in respect to their genetic variability. Therefore,
educating public about pharmacogenetics plays an important role in a successful
pharmacogenetics implementation in the clinical settings (Zhang et al., 2014).
Cytochrome P450 (CYP450) family of enzymes
Most of the genes investigated in PGx drug panels encode enzymes of the
cytochrome P450 family of enzymes. These enzymes are synthesized in the liver and they
are responsible for metabolizing numerous prescribed drugs. Different alleles are
analyzed for each gene. In this study, alleles investigated were chosen due to a) their
association with the alteration of enzymatic activity, b) their association with increasing
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side effects of specific drugs and c) their role in drug- drug interaction. Different alleles
are associated with decreased CYP450 enzymatic activity, causing a decrease in the
metabolism of certain drugs. The rate at which a drug is metabolized determines its
effects on the targeted tissue. For example, decreasing drug metabolism in respect to
inhibited enzyme activity can lead to increased drug concentration and consequently
increase its toxicity. Alternately, inducing enzyme activity leads to higher rate of drug
degradation and therapeutic levels will not be reached as a result of decreased drug
bioavailability.
Multiple drugs can play an important role in altering the effects of CYP450
enzymes by inducing or inhibiting these enzymes. Below are common
drugs/supplementations that affect CYP450 activities:
Inducers:
Phenytoin, phenobarbital, rifampin, carbamazepine, ginseng, oral contraceptive
and griseofulvin.
Inhibitors:
Ritonavir, amiodarone, cimetidine, macrolides, cranberry juice, omeprazole,
quinidine and SSRIs.
Genes targeted in the PGx drug panel
The following section will describe 12 different genes that are targeted in the PGx
drug panel. These genes were selected because of their importance in the metabolism of
commonly prescribed drugs. For each drug the following information will be presented:
clinical relevance, drug-drug interaction, and targeted alleles of interest.
CYP1A2
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On the genetic mapping CYP1A2 was found on chromosome 15q24.1 sharing the
same 5' flanking region with CYP1A1. This enzyme is highly susceptible to the
stimulatory effects of many drugs such as carbamazepine, phenytoin and rifampin.
Similarly, a wide spectrum of drugs inhibit CYP1A2 like isoniazid, zileuton and
rofecoxib. Those effects do not control the clearance of all drugs that have first pass
metabolism in the liver, only drugs that is catabolized by the same enzyme would show a
variation in their bioavailability. For instance, zileuton has an expressive
pharmacokinetics effects on antipyrine and propranolol, while its effect on other agents;
that are not metabolized by CYP1A2, were unnoticeable. Two alleles were tested;
CYP1A2*1F and CYP1A2*1K, studies showed that patients with CYP1A2*1K tend to
have a significant decrease in the enzyme activity. On the opposite side, environmental
factors such as tobacco smoking induce enzyme activation so increasing drug dosage
would be required. The importance of this enzyme came from its ability to activate many
endogenous chemical substances in the body and convert pro-carcinogens compounds
into carcinogens through its oxidative characteristics (S. F. Zhou, Wang, Yang, & Liu,
2010).
CYP2B6
This gene takes its significance from being a highly polymorphic gene implicated
in the transcription, splicing and translation of mRNA which create a variation in protein
expression. Adding to that, the excretion of enzymes coded by this gene is not only
limited to the liver but it was also found in extrahepatic systems as the respiratory and
gastrointestinal tissues. One of the characteristics these tissues share, is their ability to
provide a protection barrier against different environmental toxins, which highlight the
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impotence of this gene in detoxifying these chemicals. One of the most studied drugs
metabolized by CYP2B6 is efavirenz which is used in combination with other agents to
treat HIV positive patients. Efavirenz belongs to NNRTIs; a group of drugs that inhibit
viral DNA synthesis from RNA template. Close monitoring of drug concentration should
be considered as it has a low therapeutic index. Efavirenz toxicity can cause
neuropsychiatric symptoms that is found to be associated with Q172H variant on
CYP2B6*6 allele. It was found that the presence of this allele was associated with a down
regulation in protein translation which leads to 50-75% decrease in enzyme activity that
cause decrease in dug elimination and increase drug toxicity(Hedrich, Hassan, & Wang,
2016; Y. Li et al., 2013; Zanger & Klein, 2013).
CYP2C19
This highly variable gene; more than 80 SNPs has been related to CYP19, is
responsible for the metabolism of wide range of drugs such as:


Proton pump inhibitors (omeprazole): used to treat ulcer disease induced by
helicobacter pylori and GERD.



Anti-depressants (citalopram, clomipramine): to treat depression.
(Amitriptyline): treat depression and migraine headaches.



Antiplatelet aggregation drugs (clopidogrel): in cardiovascular disease.



Aromatase Inhibitors (AI): used in substitution to anti estrogenic agents in
patients who lack CYP2D6 gene activity, AI has been prescribed to
postmenopausal women to suppress estrogen conversion in the peripheral
tissues.
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Different alleles were studied in comparison to the wild type (CYP2C19 *1/*1)
that codes for a normal metabolizer. It was found that the homozygosity of CYP2C19 *17
allele was associated with lower drug concentrations because of increased enzyme
activity. The increase in enzymatic metabolic functions was mediated by activation of
transcription factors that enhance gene transcription of CYP2C19 gene. This phenotype
variant plays its effect on the metabolism of anti-depressants and proton pump inhibitor
agents (Hicks et al., 2013; Sim et al., 2006).
CYP2D6
The CYP2D6 is the most detected gene in PGx testing as it is an important
indicator in the metabolism of psychiatric medications (Wolf et al., 2000). Although this
enzyme present in small quantities in the CYP450 family, its role is highly relevant as it
accounts for metabolizing more than 25% of the most commonly prescribed drugs. In
addition, studying this gene polymorphism is very important as it interferes highly with
the pharmacokinetics of nearly 50% of the most commonly prescribed drugs. This
enzyme metabolizes chemotherapeutic agents like tamoxifen; anti estrogenic agent used
to treat breast cancer, by converting it to its active metabolites. Increased active amounts
of this enzyme are found to be related to lower drug concentrations and higher adverse
effects of the affected drug. For instance, more active levels of CYP2D6 leads to lower
concentrations of tamoxifen and increase vomiting severity as an adverse effect of this
agent. MDMA, which is a psychoactive drug that increases the stimulant neurotransmitter
levels in the synaptic cleft, is metabolized by CYP2D6. Interestingly, it is a potent
inhibitor of CYP2D6 and dramatically decreases the enzyme levels, thus continuous use
of these substances leads to overdose toxicity as the enzyme that degrade these
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metabolites is blocked. Decrease enzyme activity was associated with *10 and *14 allele.
Concomitant use of drugs that inhibit CYP2D6 may lead to inactivation of the gene and
predispose the patient to be a poor metabolizer even though, the patient genotype
detected as normal metabolizer(Hicks et al., 2013; Ingelman-Sundberg, 2005; Mas et al.,
2012; Wolf et al., 2000; S.-F. Zhou, 2009).
CYP3A
CYP3A is a very important enzyme in drug metabolism as it is considered as the
most active enzyme responsible for clearance of the majority of prescribed drugs like
midazolam, erythromycin, cyclosporine and diltiazem. High quantities of this enzyme are
commonly detected in both the liver and intestines. Genetic mutations of this enzyme are
implicated in the alteration of enzymatic activity. Research aimed to detect potential
causes of genetic mutations of this gene, showed that the variation in exons and introns
likely alters enzymatic activity and quantity.
Several drugs may either enhance or inhibit CYP3A activity, thus drug-drug
interactions should be cautiously checked among individuals with altered CYP3A
activity, as they may be at higher risk of serious and even life threatening side effects. For
example, antifungal agents, nitromedazole, verapamil and diltiazem are all CYP3A
inhibitors. Administration of these agents concomitantly with other agents metabolized
by the same enzyme’ like erythromycin, would lead to decrease erythromycin clearance
with an increase in its toxic effects. Erythromycin toxicity may cause QT prolongation
that may develop to torsade de point and sudden cardiac death. Similarly, the
consumption of grapefruit; which is CYP3A inhibitor; simultaneously with Calcium
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Channel Blockers (CCB) can lead to extensive vasodilation and reflex tachycardia as a
side effect of calcium channel blockers’ adverse effects.
Interestingly, this phenomenon of drug-drug interaction can aid in some of the
treatment methodologies to eradicate certain viruses. Antiretroviral medications, which
are used to slow the rate of Human Immunodeficiency Virus HIV replication, are
required to be in high concentrations in order to reach the therapeutic benefits. To
achieve this goal, ritonavir is administered with other protease inhibitors to increase their
level in the plasma. Ritonavir is a CYP3A inhibitor which decreases CYP3A enzymatic
function in both the liver and the intestines. Other protease inhibitors are metabolized by
the same enzyme (CYP3A); therefore, their plasma concentration would be increased
appropriately in response to the attenuation of CYP3A enzyme activity. Another
mechanism by which ritonavir increases other drug concentrations in the body is by
blocking the P-glycoprotein on the intestinal wall. P-glycoprotein, also known as Multi
Drug Resistance Protein-1 (MDR1), has an ATP dependent efflux pump on the cell
membrane that prevents the accumulation of drugs intracellularly. Consequently this
action inhibits the absorption of several drugs and facilitates their excretion in the
intestinal lumen (Bofitto, 2004; Lamba, Lin, Schuetz, & Thummel, 2012; Wilkinson
2005; Yasuhara, 2006).
ANKK1/DRD2
These two genes act as a receptor in the dopaminergic pathway. Dopamine is the
main neurotransmitter that controls movement regulation, cognitive status and prolactin
secretion. It acts via three different physiological pathways: nigrostriatal, mesocortical
and tuberoinfundibular. Damage of dopaminergic neuron in the basal ganglia contributes
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to Parkinson disease. In contrast, the increase in dopamine is implicated in schizophrenia
and Huntington disease. Antipsychotics medications antagonize the D2 receptor causing
drug-induced Parkinsonism by blocking D2 receptors in the nigrostriatal pathway. The
irreversible effects of inducing tardive dyskinesia is highly associated with the A2-A2
genotype on Taq1A in DRD2 gene. Other studies have shown that patients who have
DRD2*A1 allele were more susceptible to experience hyperprolactinemia as a side effect
of using antipsychotics (Bakker, van Harten, & van Os, 2008; Huang et al., 2009; Young
et al., 2004).
COMT
This gene codes for the COMT enzyme that is found in the liver and brain. It
plays an important role in the degradation of catecholamines neurotransmitters.
Decreased activity of this enzyme causes accumulation of dopamine; increased dopamine
concentration is one of the drug mechanisms used to treat Parkinson disease.
Polymorphisms of the COMT gene result from the substitution of valine amino acid with
methionine (Val158Met). The outcome of this variation is a methionine variant that has a
lower action on catalyzing neurotransmitters in the dopaminergic pathway. The increased
dopamine concentration, as a result of the methionine variant, is likely responsible for the
wide variation in physiological responses to neurostimulants, such as amphetamine, used
to treat ADHD. Research showed that people with valine variant (wild type Val/Val) of
the COMT gene tend to have better drug efficacy to neurostimulant agents as they have
lower pre-treatment concentration of dopamine in their synapses, compared to those with
the methionine variant. Similarly, modulating the dosage of morphine is required
depending on the genotype. Higher doses of morphine were administered to patients
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holding homozygous valine genotype, compare to those with homozygous methionine
genotype, in order to provide the same level of pain relief (Bellgrove et al., 2005; MeyerLindenberg et al., 2006; Rakvag et al., 2005).
OPMR1
Analgesics antagonize opioid receptors in the body, such as mu beta-endorphin
opioid receptor (OPMR1), and alterations in the OPMR1 gene influence a wide range of
variation in response to opioids among patients. Although different loci in the OPMR1
gene still need to be further investigated, strong associations were found between altered
pain threshold and the single nucleotide polymorphism G variant at position 118
(A118G). This missense mutation substitutes the amino acid asparagine with aspartic
acid, resulting in decreased glycosylation on the N-terminal site. This missense mutation
is associated with altered pain sensitivity, so dosage modulation of opioids is required
accordingly. Patients who are homozygous to guanine variant (G/G) genotype require
higher doses of morphine compared to those with the normal adenine (A/A) genotype.
However, there are still controversial speculations regarding the heterozygous (A/G)
genotype. Research indicates that the fluctuation in opioid response is dependent on the
clinical setting such as labor, cancer, postoperative or chronic disease. Additionally, other
investigations suggest that ethnicity may be a potent contributor to this diversity (Hwang
et al., 2014; Rhodin et al., 2013; Shabalina et al., 2009). To summarize,
pharmacogenetics testing implications in aesthetic drugs still at the early beginnings and
further inspections of mutations in other genes; like ABCB1, CYPs, or UGT’s, that may
be involved in response variation yet to be studied (Hwang et al., 2014; Rhodin et al.,
2013; Shabalina et al., 2009).
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SLCO1B1
Solute Carrier Organic Anion Transporter family member 1B1 (SLCO1B1) is the
gene encoding the protein responsible for the transport of different chemicals, including
drugs, to the liver in order to be metabolized. This gene was found to be implicated in
several clinical implications such as bladder cancer, hematologic malignancy, and
myopathy (J. Li, Wang, X.-R., Zhai, X.-W., Wang, H.-S., Qian, X.-W., Miao, H., & Zhu,
X.-H. , 2015). The following are examples of its clinical relevance:
 The allele GG/AG at SLCO1B1 rs2306283 gene has been associated with bladder
cancer, decrease arsenic detoxification thought to be the culprit of this process. Arsenic is
a carcinogen that is involved in toxic reduction reaction and it predispose to squamous
cell carcinoma in the bladder, it is commonly associated with occupational exposure (Bui,
Fujimoto, Kubo, Inatomi, & Matsumoto, 2014; Gribble et al., 2013).


SLCO1B1 on chromosome 12 codes for a membrane transporter called OATP1B1

responsible for the efflux of one methotrexate; a chemotherapeutic agent used in the
treatment of acute lymphoblastic leukemia ALL, which is the most common hematologic
malignancy in children. Increase in methotrexate toxicity was found to be related to two
different genotype in the SLCO1B1 gene; rs4149081AA and rs11045879CC (J. Li,
Wang, X.-R., Zhai, X.-W., Wang, H.-S., Qian, X.-W., Miao, H., & Zhu, X.-H. , 2015).
 One of the commonly prescribed drugs that are highly affected by SLCO1B1
variant is statins. Statins are lipid lowering agents that decrease LDL, increase HDL and
decrease the risk of cardiovascular complications. The most common observed adverse
effect of using statins is myopathy, which may range from moderate to severe in some
cases. Studies showed that there is a strong association between the statin-induces
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myopathy and variant 521T>C (rs4149056) on the *5 allele which decrease the function
of SLCO1B1. Furthermore, TT genotype was found to prevent the development of
myopathy, while C allele predispose to myalgia (Group, 2008; Linde, Peng, Desai, &
Feldman, 2010; Stewart, 2013).
MTHFR
Methylenetetrahydrofolate reductase is the rate-limiting enzyme that irreversibly
converts 5, 10 methylenetetrahydrofolates to 5 methylenetetrahydrofolates (5 MTHF). It
is encoded by the MTHFR gene. In order for folate to be in the active form (5 MTHF), it
first needs to be reduced by the MTHFR enzyme. Folate plays an important role in the
synthesis of nitrogenous bases in DNA and RNA. It serves as a coenzyme for 1-carbon
transfers in the cysteine cycle that regulate homocysteine levels in the blood. A mutation
in MTHFR gene, found on chromosome 1 (p36.3), may lead to impaired DNA repair,
DNA hypomethylation, folate deficiency and even an increase in homocysteine levels
(Del Greco et al., 2011). Below is a description of the different allelic variants detected in
MTHFR gene that are clinically relevant:
 MTHFR gene mutation and kidney pathology: It was proposed that the main
predictor of 5 MTHF activity as a metabolite that facilitate homocysteine conversion to
cysteine is a SNPs on MTHFR gene; C677T polymorphism. This mutation is implicated
in reduced enzyme MTHFR activity causing hyperhomocysteneimia, increased
homocysteine levels predispose to increase risk of thrombosis and cardiovascular
diseases. Moreover, C677T polymorphism in combination with another mutation;
A1298C (rs1801131, Glu429Ala) in Exon 7, showed to cause hypertensive
nephrosclerosis in patients with renal failure; additionally, both mutations can lead to
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hyperhomocysteinemia. Interestingly, these complications were noticeable in individuals
with the C677T mutation alone, but not with individuals who express just the A1298C
polymorphism (Fung et al., 2012).
 MTHFR and cancer risk: The association between MTHFR A1298C
polymorphism and malignancy has been found to be related to the cancer site and
ethnicity. A1298C was associated with increased risk for lymphoma and cervical cancer;
controversially, it was linked to decrease colorectal cancer risk. Both increase and
decrease malignancy risk was detected in Asian population in specific (Zhu et al., 2016).
 MTHFR and BNP (B-type natriuretic peptide): It was proposed that the variant on
a specific gene may show interaction with variants located on other genes; therefore,
MTHFR gene was studied among a group of genes MTHFR-CLCN6-NPPA-NPPB gene
cluster. Although the four genes were associated with BNP levels; BNP plasma levels are
used to rule out heart failure, robust association was found with MTHFR C688T
polymorphism. This relation between the variant in the gene cluster and the BNP was
also related to hypertension; however, systolic blood pressure was highly related to a
SNP on MTHFR gene as well. The influence of C677T polymorphism is not exclusive to
the pathology of the disease solely, but it was related to the treatment choices; for
example, the response to ACEI; anti-hypertensive medication, is affected by the C677T
polymorphism (Del Greco et al., 2011; Fung et al., 2012).
 MTHFR gene and ASD: MTHFR deficiency is associated with increased
oxidative and decreased reduced metabolites in the transsulfuration pathway of
homocysteine, that creates a metabolic imbalance and increase the risk of oxidative stress
which was noticed in autistic children. Additionally, MTHFR gene heterozygote mutation
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has been strongly associated with hyperhomocysteinemia which predispose to
cardiovascular diseases as it increases the oxidative stress and decreases nitric oxide that
has vasodilatory effects; consequently, MTHFR gene variant underlies an early onset and
increase susceptibility to a hypercoagulable state (James et al., 2006; Kim, Lee, Kim,
Kim, & Yoo, 2013; Pramukarso, Faradz, Sari, & Hadisaputro, 2015). Folate and B12
vitamin supplementation are administered in patients who have MTHFR deficiency to
reduce the risk of thrombosis (Kim et al., 2013). These vitamins are also used in the
treatment of autism as it improves the behavioral symptoms; however research showed
that prenatal vitamin supplementation played an important role in preventing autism
occurrence in the offspring(Schmidt et al., 2011).
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Chapter Three: Methodology
Participants
Participants were recruited from clients participating in the KAP (Kelly Autism
Program) at Western Kentucky University (WKU). The KAP is housed in the Suzanne
Vitale Clinical Education Complex (CEC) on the WKU campus, and the program
provides a variety of services to those diagnosed with ASD, as well as to their families.
A research team member was responsible for identifying potential participants
and contacting their caregivers/legal guardians to share information about the study. All
participants and their caregivers were involved to give utmost consideration to the unique
and specific needs of the participants, who represent a particularly vulnerable population.
All of the investigators have extensive experience with conducting research with
vulnerable populations, in general, and with children with ASD, in particular. This
interdisciplinary research team brings unique strengths and skills that involve consenting
children and their parents in primary data collection activities and are aware of the
necessary steps that must be taken to safeguard them not only from undue risks. All
potential participants were given an informational brief (Appendix A) and a copy of the
caregiver informed consent (Appendix B). In each case, participants and their caregivers
were aware of risks and requirements for participating. It was communicated that
participation was completely voluntary and would not affect their KAP programming in
any way. The testing that was performed in this study was performed with the best
interests of the child in mind. All participants for this study met the following inclusion
criteria:
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1) There was documentation that the student has been identified by a third party
professional as having an Autism Spectrum Disorder,
2) The student was between the ages of 7-17,
3) The student had a current or past sleep disturbance, as measured by caregiver
report,
4) The student was currently taking a daily medication.
As the study sample for this project was composed of minors with a disability,
there were multiple steps to the consent process. All caregivers had to complete a
written informed consent (Appendix B). Additionally, four separate assent documents
were created targeting the unique communication methods of participants with ASD
(Appendices D-G).
A research team member was available for in-person meetings or phone
conferences to answer all questions the caregivers might have had regarding the study.
Once parents signed the consent document, they were asked to identify their child’s most
common communication method (Appendix C).
This information was used to obtain child consent. Caregivers were asked to
identify one of four categories of communication:
(a) The child can sign his/her name to give consent;
(b) The child can check a box to give consent;
(c) The child can use sign language to give consent, or
(d) The child can use a communication device to give consent.
Once informed caregiver consent was obtained, one of the investigators or their
designee acquired participant assent.
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One of the investigators trained in working with students with ASD read one of
the four assent documents associated with the child’s most common method of
communication. The investigator was instructed to read the script exactly as it was
written and then prompt a response from the participant. Once informed caregiver and
participant assent had been obtained, the PI then collected information about whether the
participant met inclusion criteria. If the participant met inclusion criteria, he/she was
placed in a pool to be randomly selected for inclusion in the study. If the participant did
not meet inclusion criteria, a letter was sent to the informal caregiver explaining that the
student was not eligible for participation in the study. A total of fifteen (15) participants
with ASD were selected to participate in the study.
Blood Sampling
The blood draw procedures coincide with the guidelines set forth by the U.S.
Department of Health and Human Services Office for Human Protections Research.
Blood samples were obtained using Universal Precautions at rest, and approximately 5
ml of venous blood was drawn from the cubital or cephalic vein of each participant’s
arm. Each participant had only one blood draw. All blood draws will be done by a
skilled professional trained in phlebotomy from the Exercise Physiology laboratory in
the School of Kinesiology, Recreation & Sport (KRS).
The phlebotomist doing the blood draw also had a brief training by the
investigators regarding blood draws from children with ASD. The training was
centered on the guidelines and suggestions in the “Phlebotomy Toolkit for Providers
Treating Children with Autism”, and it was ensured that the research group was
adequately prepared with proper accommodations and supports. Additionally, one of the
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investigators (specifically trained to work with students with ASD) was present during
the entire duration of the blood draw for each participant. To minimize risks to study
participants and to identify potential support prior to bringing children in front for a
blood draw, a checklist was provided to the parent to ensure that it is a good fit for the
child and that the parent believes the child was prepared to have his/her blood drawn
(Appendix C).
Blood draws were done in a classroom at the CEC that is designated for blood
draws during the duration of this study. The participants were recruited from programs
at SVCEC, so they were in a familiar, comfortable environment. The duration of each
blood draw depended on the behavior and willingness of each participant but it was
anticipated that they will take anywhere from two minutes to fifteen minutes. If at any
time, the participant expressed anger or discomfort with the blood draw, the blood draw
was immediately stopped.
Blood draw procedures were as follows:
1. Wrap a tourniquet around the patient's upper arm to stop blood flow;
2. Sterilize the puncture site with alcohol;
3. Insert the needle into the vein with the bevel up;
4. Attach the appropriate test tube to the needle. Allow the blood to fill the test
tube;
5. Remove the tourniquet to restore blood flow;
6. Place a gauze pad over the site while withdrawing the needle; and
7. Apply firm pressure to the site until bleeding has stopped
Blood Storage and Transport
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Individual vials of participants’ blood labeled and coded appropriately for
anonymity. It was stored in the KRS Exercise Physiology laboratory at a temperature of
-80*C until it is shipped to MyGenetx in Franklin, Tennessee for genetic analysis.
Shipping was done in small batches (3 –5 vials per batch) via FedEx. All procedures for
maintaining integrity of the blood, as well as appropriate measures for confidentiality,
were followed for shipping.
Genetic Analysis of Blood
All genetic analyses of participants’ blood was conducted at MyGenetx in
Franklin, Tennessee. MyGenetx is a molecular and general chemistry laboratory
involved in research concerning pharmacogenetics, chronic disease management,
oncology, and endocrinology, as well as other current health issues.
Genetic analysis procedures were as follows:
1. Next generation sequencing (NGS) is performed in three steps that begin with
the generation of a template. Template preparation consists of building a library of
nucleic acid and amplifying that library.
2. Sequencing libraries are constructed by fragmenting the DNA sample and
ligating adapter sequences onto the ends of the DNA fragments.
3. Once constructed, libraries are clonally amplified in preparation for sequencing.
4. Following template preparation, nucleic acid sequencing occurs from the
amplified libraries; the platform relies on sequencing by synthesis.
5. The library fragments act as a template, off of which a new DNA fragment is
synthesized.
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6. The sequencing occurs through a cycle of washing and flooding the fragments
with the known nucleotides in a sequential order. As nucleotides incorporate into the
growing DNA strand, they are digitally recorded as sequence.
7. Once sequencing is complete, raw sequence data must undergo several analysis
steps.
8. A generalized data analysis pipeline for NGS data includes preprocessing the
data to remove adapter sequences and low-quality reads, mapping of the data to a
reference genome or de novo alignment of the sequence reads, and analysis of the
compiled sequence.
9. Analysis of the sequence can include a wide variety of bioinformatics
assessments, including genetic variant calling for detection of SNPs or idles (i.e., the
insertion or deletion of bases), detection of novel genes or regulatory elements, and
assessment of transcript expression levels.
10.

Analysis can also include identification of both somatic and germline

mutation events that may contribute to ASD and sleep disturbance.
11.

Analysis of the data will include incorporation of proteomic,

metabolomics, transcriptomic, immunomic, signaling pathways and disease data to
identify unique molecular connections. These unique connections are placed under
increasing stringency to identify genes with the highest probability of connection to
ASD and sleep disturbance.
12.

The overarching goal of the analysis is to identify genes that play a role

in the pathogenesis and progression of ASD and to identify potential therapeutic targets.
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13.

The identification of targets can allow for the personalization of therapy

for each patient based on the individual genomic map that is produced.
All information was de-identified before delivery to the MyGenetx laboratories.
MyGenetx never had information that connects an individual participant with their
blood draw. Electronic data were numerically coded for anonymity and stored in a
password-protected document on a password-protected computer
Drug Panel
The results of the pharmacogenetics testing were reported as a summary of the
selected genes with their specific genotype, phenotype and the alleles that were tested.
Most of the potential drugs, affected by the detected genes that may be used currently or
over the participant’s life time, were listed. According to the personalized genotype,
medications were classified as drugs to use with standard precautions, drugs to use with
caution and drugs that need to consider alternatives.
Following these classifications, a detailed dosing guidance; as predicted by the
participant’s genotype; was provided for each medication belongs to the use with
caution category. A description of individual’s level of sensitivity to the drug and the
recommended dosage adjustment to reach the desired response was proposed. Adding to
that, all the adverse effects that may occur as a response to high drug doses or as a
complication of environmental factors; such as smoking or smoking cessation; was
mentioned. Close monitoring of specific body vital signs, organ functions or blood cell
count measurements was advised when using drugs that may cause alteration in these
parameters. Moreover, drug substitution was suggested for the category of agents
classified as consider alternatives. At the end, a focused literature review including an

25

assay interpretation, clinical utility and clinical implementations of each gene was
provided.
Survey and Training Session
Survey
A pre-training survey was designed to estimate the knowledge of, attitudes
towards, and future expectations of pharmacogenetics among the guardian’s
participants. These surveys were administered before the pharmacogenetics results
training session (lead by a research team member). The level of knowledge was
detected by asking questions about their understanding of the healthcare application of
pharmacogenetics and about how familiar they are with pharmacogenetics. Other
questions in the survey related to their attitude measured how interested they were in
learning about pharmacogenetics or how they rate the impotence and beneficial role of
pharmacogenetics. Additionally, their level of confidence regarding communication
with their doctor about pharmacogenetics was assessed. Likewise, the parent’s
expectations that pharmacogenetics testing results would enable their physicians to
prescribe better choices of drugs were questioned. Participants were directed to answer
the survey to the best of their understanding.
Post-training surveys, identical to the pre-training surveys, were administered to
compare how participants responded to the training session.
Training Session
A training session was conducted to help the participants gain better
understanding of the results depicted in the drug panel. A brief introduction describing
the principles of how and why an individual may respond to medications was given.
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The leader of the training session described how individuals respond to medications
differently, despite the medication having the same mechanism of action. Participants
were informed that this concept is the basis of an emerging field of study called
pharmacogenetics, which is the study of gene-medication interaction. Additional
information regarding the explanation of how genetic variations likely cause
individualized responses to different medications was explained.
During the training session, a summary of the steps needed to for
pharmacogenetics testing was described as following:
1. Conduct a blood draw
2.

DNA is isolated in the lab

3. Unique marker in DNA are identified
4. These markers give clues about how medicines will work, because
medicines work differently in different people
The training session explained how the genes selected to be analyzed are
implicated in the metabolism of the most commonly prescribed medications that the
children may be taking currently or may take during their life time. These genes control
the efficacy of the drugs and classify medications in three categories: standard
precautions, use with caution (for drugs that cause adverse effects) and use alternatives
(either because of reduced response or increased sensitivity to the drug).
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Chapter Four: Attitudes, Knowledge and Future Expectations towards Pharmacogenetics
among Families of Children with Autism Spectrum Disorder
Abstract
Pharmacogenetics is the study of genomic-guided individualized drug prescription
that plays an important role in preventing the severe adverse effects of drugs, decreasing
the time and cost of therapeutic choices, and directing healthcare professionals to choose
medications that are effective and safe. It is noteworthy that this approach becomes
highly beneficial in patients suffering from chronic diseases or disorders, since these
conditions may require multiple and long term pharmacological therapies, as in children
with autism spectrum disorder (ASD). However, public acceptance is a major challenge
when implementation of pharmacogenetics merges into clinical practice. The purpose of
this study is to inspect the knowledge of, attitude towards and future expectations with
regards to pharmacogenetics among parents of children with ASD. A group of 15 schoolaged participants with ASD were recruited for the study. Approximately 5 ml of venous
blood was drawn for each participant to analyze the genotype of enzymes implicated in
drug metabolism via pharmacogenetics testing. Thereafter, the parents of these children
attended a training session to help them gain a better understanding of the
pharmacogenetics results depicted in the drug panel results. A pre-training and posttraining survey was conducted to assess the knowledge of, attitude towards and future
expectations of pharmacogenetics among the children’s parents.
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Introduction
Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder (ASD) is a neurodevelopmental disability
characterized by restricted interests, repetitive behaviors and deficits in
communication and social reciprocity skills (White, Keonig, & Scahill, 2007). Due to the
prevalence of children identified with ASD (1 in 68 children), there is a need for
interventions targeting the specific characteristics children and adolescents with ASD
display (Center for Disease Control and Prevention, 2014).
Characteristics of Autism Spectrum Disorder
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), there
are five factors that make up the diagnostic criteria for ASD. The first feature includes
deficits, which persist over time, in social communication and social interaction. These
deficits can include, but are not limited to, abnormal social approach, failure to grasp the
pragmatics of normal conversation, failure to start or participate in social interactions,
abnormal eye contact and body language, failure to develop and maintain social
relationships, difficulties initiating or maintaining friendships, and a lack of interest in
peers. The second factor includes restricted and repetitive behaviors and interests.
Examples of this type of behavior include, but are not limited to, repetitive speech,
insistence on adhering to routines, highly restricted perseverative interests with an
abnormal intensity, and unusual sensory interests. The third factor says that the symptoms
must be present in the early developmental period. The fourth factor says that the
symptoms cause clinically significant impairment in certain areas of functioning. The
final factor says that the symptoms are not better explained by another disability.
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Pharmacological treatment of ASD
Medications are one of the multiple interventions used to treat autism. The
concomitant use of multiple therapies was common due to the comorbidity nature of the
disease; thus detecting the efficacy of the treatment was further complicated (Bowker et
al., 2011; Zane et al., 2008). However, medications; that are used to treat comorbid rather
than main symptoms of the disease, has been reported to be one of the most frequently
discontinued treatment methods (Bowker et al., 2011; McPheeters et al., 2011).
Therefore, the increasing demands on pursuing pharmacological choices, the unclarity of
efficacy and the alarming adverse effects of some of the drugs with the high cost of these
modalities, prompt the need for further investigation in the field (Bowker et al., 2011;
Zane et al., 2008).
Research that reviewed the most commonly prescribed medications used in the
treatment of autism addressed the following classes of drugs; antipsychotics, SSRIs (as
part of anti-depressants) and anti-ADHD agents (McPheeters et al., 2011), clinical use
of these agents improves challenging behaviors (irritability, aggression and selfinjurious behavior), repetitive behavior and hyperactivity respectively. Although
antipsychotics; particularly aripiprazole and risperidone, are proved to be efficacious,
sever adverse effects were observed when using these agents as 30% of patients using
aripiprazole were susceptible to weight gain. The adverse effects of atypical
antipsychotics manifested by weight gain, sedation and extrapyramidal symptoms
(McPheeters et al., 2011; Stachnik & Gabay, 2010).
Although both citalopram and fluoxetine are agents from the SSRIs category,
their targeted benefits were found to be divergent. While fluoxetine improves repetitive
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behavior, citalopram ameliorates challenging behavior. Other class of medications that
was used by 30-85% of children with ASD is anti-ADHD, these neurostimulant
medications were prescribed to provide a short-term relief for symptoms of hyperactivity
and impulsivity (Dalsgaard et al., 2013; McPheeters et al., 2011). Regardless of the
beneficial effects of medications used to treat autism, close monitoring is required as they
may cause serious adverse effects because of the long term use of these
medications(McPheeters et al., 2011).
Having a Prospective expectations of the possibility to develop potential adverse
effects of the most commonly prescribed drugs for patients with ASD, can protect the
patients from being predisposed to avoidable adverse effects of these drugs in addition to
saving money and giving the time for other therapeutic choices to be prescribed. That
critical goal can be accomplished by requesting a pharmacogenetics testing (Bowker et
al., 2011; Wolf et al., 2000; Zane et al., 2008)
Pharmacogenetics (PGx)
What is pharmacogenetics?
Pharmacogenetics is the study of genes that affect the response of the medications
in the body. In some literature pharmacogenetics is used interchangeably with
pharmacogenomics; however, other literature defined pharmacogenomics as the study of
the interaction effects in between genes (Zhang et al., 2014). A number of literature
divided the study of PGx into two aspects:


The study of the genes associated with specific diseases that can be targeted
by medications
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The study of genetic variability that can alter drug response (Wolf et al.,
2000).

Medications demonstrate its action on the body by working at three levels: the
enzymes metabolizing the drug, the signaling pathway and the receptor on the targeted
tissues (Ensom et al., 2001). Most of the identified genetic variation is a result of single
nucleotide polymorphism SNPs that change the coding for a group of enzymes implicated
in metabolizing medications (Ensom et al., 2001). The outcome of these SNPs may range
from delayed response, increased toxicity, extended effect, adverse reaction or drug-drug
interactions(Wolf et al., 2000). Thus, DNA analyzed by the pharmacogenetics testing
would provide an individualized information about the efficacy and safety of the
prescribed medications (McCarthy, 2001).
Beneficial Role of Pharmacogenetics
One of the studies indicated that 1 in 15 hospital admissions is related to side
effects of the drugs(Wolf et. al., 2000); whereas among children, adverse effects count
for 2%-4% of hospital admissions and 3% of out-patient visits (Zhang et al., 2014).
Therefore, being knowledgeable of the personalized adverse effects prospectively; by
detecting the genetic coding of enzymes responsible for the metabolism of the prescribed
drugs, would reduce the cost, time and harmful events (Bowker et al., 2011; Zane et al.,
2008).
Many patients are deprived from pharmacological choices because the standard
dose of this medication may accumulate in their body leading to drug related toxicity.
The situation becomes even more critical when the pharmacological choices are
lifesaving as in oncology patients(Drew, 2016). Pharmacogenetics testing enable the

32

physicians to overpass all these obstacles by establishing a constant “personal
pharmacogenetics profile”. This profile can provide recommendations of the type, dosing
and alternative of the drugs that may be prescribed during the patient’s life time;
consequently, healthcare providers can make their decisions based on the genetic
information of the patient (Wolf et al., 2000).
Knowledge and Attitude towards Pharmacogenetics
The future of pharmacogenetics is highly promising; nonetheless, public
acceptance is still the cornerstone of pharmacogenetics’ prosperity (Innocenti et al., 2000;
Zhang et al., 2014). Research showed that people enthusiasm about pharmacogenetics
vary between general population and those who are suffering chronic diseases (Zhang et
al., 2014). Adding to that, the baseline understanding of PGx and the health condition had
a significant effect on the individual’s level of comfort to perform a pharmacogenetics
testing (Innocenti et al., 2000). It is noteworthy to mention that even though public
showed interest to do a PGx testing, they do not seem to be compliant to the test results.
In other words, they would take the medication regardless of the fact that it can cause
serious side effects or even if the drug is contraindicated in respect to their genetic
variability. Therefore, educating public about pharmacogenetics plays an important role
in a successful pharmacogenetics implementation in the clinical settings (Zhang et al.,
2014).
Methods
Nine parents of children with ASD; who were recruited to do the
pharmacogenetics testing, attended a training session and performed a survey.
Survey
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A pre-training survey was designed to estimate the knowledge of, attitudes
towards, and future expectations of pharmacogenetics among the guardian’s
participants. These surveys were administered before the pharmacogenetics results
training session (lead by a research team member). The level of knowledge was
detected by asking questions about their understanding of the healthcare application of
pharmacogenetics and about how familiar they are with pharmacogenetics. Other
questions in the survey related to their attitude measured how interested they were in
learning about pharmacogenetics or how they rate the impotence and beneficial role of
pharmacogenetics. Additionally, their level of confidence regarding communication
with their doctor about pharmacogenetics was assessed. Likewise, the parent’s
expectations that pharmacogenetics testing results would enable their physicians to
prescribe better choices of drugs were questioned. Participants were directed to answer
the survey to the best of their understanding.
Post-training surveys, identical to the pre-training surveys, were administered to
compare how participants responded to the training session.
Training Session
A training session was conducted to help the participants gain better
understanding of the results depicted in the drug panel. A brief introduction describing
the principles of how and why an individual may respond to medications was given.
The leader of the training session described how individuals respond to medications
differently, despite the medication having the same mechanism of action. Participants
were informed that this concept is the basis of an emerging field of study called
pharmacogenetics, which is the study of gene-medication interaction. Additional
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information regarding the explanation of how genetic variations likely cause
individualized responses to different medications was explained.
During the training session, a summary of the steps needed to for
pharmacogenetics testing was described as following:
1. Conduct a blood draw
2.

DNA is isolated in the lab

3. Unique marker in DNA are identified
4. These markers give clues about how medicines will work, because
medicines work differently in different people
The training session explained how the genes selected to be analyzed are
implicated in the metabolism of the most commonly prescribed medications that the
children may be taking currently or may take during their life time. These genes control
the efficacy of the drugs and classify medications in three categories: standard
precautions, use with caution (for drugs that cause adverse effects) and use alternatives
(either because of reduced response or increased sensitivity to the drug).
Results
We conducted the survey pre and post-training to observe the effect of children’s
parents awareness on the implementation of pharmacogenetics. Nine parents of children
with ASD, who were recruited for the study, attended the training session. Results
comparing the variability in parents’ response before and after training regarding attitude,
knowledge and future expectations about pharmacogenetics are demonstrated in Table 1.
Results showed that participants’ understanding of healthcare application of
pharmacogenetics was significantly increased after the training session (p=0.008).
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Additionally, participants’ familiarity about pharmacogenetics as well as their rating of
the importance of pharmacogenetics testing was significantly increased with a P value of
(p=0.035). However, some of the attitudes and knowledge aspects trend to be increased in
response to training, since: 1) their comfort to talk to their physicians about
pharmacogenetics and their rating of beneficial role of pharmacogenetics reached a P
value of 0.081, 2) hearing about pharmacogenetics showed a trend to be increased as it
has a P value of 0.051.
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8(88% )
8(88%)

Not at all
Pre
Post

1(11%) 2(22%)
1(11%) 3(33%)
1(11%) 2(22%)

1(11%)
1(11%)

1(11%) 4(44%)

1(11%) 3(33%)

1(11%) 5(55%)

2(22%)

1(11%) 3(33%)

4(44%)
1(11%) 3(33%)

1(11%) 5(55%)

Pre

A lot
Post

1(11%)

1(11%)

3(33%) 2(22%) 4(44%)

5(55%) 2(22%) 2(22%)

2(22%) 1(11%) 5(55%)

2(22%) 3(33%) 6(66%)

2(22%) 2(22%) 6(66%)

3(33%) 2(22%) 5(55%)

A fair amount
Pre
Post

2(22%)

Moderate
Pre
Post

1(11%)

1(11%)

A little bit
Pre
Post
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3(33%)

4(44%)

7(77%)

1(11%)

A little bit
Pre
Post

1(11%)

1(11%)

1(11%)

3(33%)

5(55%)

Moderate
Pre
Post

3(33%)

Pre

5(55%) 1(11%)

4(44%)

3(33%)

A fair amount
Pre
Post

A lot

4(44%)

1(11%)

1(11%)

Post

19. I was hesitant to have my child participate in the
research study because it involved genetic analysis

15. How comfortable are you talking to your child’s
doctor about pharmacogenetics

14. How comfortable are you talking to your doctor
about pharmacogenetics

13. How interested are you in doing more
pharmacogenetics testing

How likely are you to talk to your doctor about
pharmacogenetics?

How would you rate the benefit of
pharmacogenetics testing?

How would you rate the importance of
pharmacogenetics testing?

Attitude
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1(11%)

Moderate
Pre
Post

1(11%) 1(11%)

1(11%) 1(11%)

A little bit
Pre
Post

2(22%) 3(33%) 6(66%)

2(22%) 6(66%) 7(77%)

3(33%)

1(11%) 4(44%) 7(77%)

4(44%)

4(44%)

1(11%) 7(77%) 8(88%)

2(22%)

Post

1(11%) 7(77%) 8(88%)

Pre

A lot

2(22%)

A fair amount
Pre
Post

Not at all
Pre
Post

4(44%)
I have a good understanding of
the healthcare application of 1(11%)
pharmacogenetics

How familiar are you with
pharmacogenetics?

How much have you heard about
pharmacogenetics?
1(11%)

Knowledge

16. I would ask my child’s doctor to use
my child's pharmacogenetics results
to determine the best medication for
them.

10. I would request a pharmacogenetics
test to determine my best choice
of medicine in the future.

I would ask my doctor to use
pharmacogenetics results to determine
the
best drug for me.

I would benefit from learning about how
specific genes in the body can
affect the metabolism of medication

Learning about how my body
metabolizes medications could make my
medications safer and more effective

Not at all
Pre
Post

Discussion
Our study was designed to detect the significance of educating the public towards
pharmacogenetics. Our participants were from families have a child with ASD who may
chronically be in need to pharmacological interventions, hence the gene-drug interactions
study is highly beneficial in this special population. The baseline survey before the
training indicated a limited knowledge of pharmacogenetics among participants which
was significantly improved after the training. This finding emphasizes the need to pursue
awareness plans about pharmacogenetics.
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Chapter Five: Pharmacogenetics Study among Children with Autism Spectrum Disorder
Abstract
Pharmacogenetics is the study of genetic-guided individualized drug prescription
that plays an important role in: preventing severe adverse effects of the drugs, decreasing
the time and cost of therapeutic choices and directing healthcare professionals to choose
medications that are effective and safe. It is noteworthy that this approach becomes
highly beneficial in patients suffering from chronic diseases or disorders, since these
conditions may require multiple and long term pharmacological therapies; as in children
with autism spectrum disorder ASD. The purpose of this study is two-fold: a) to
investigate the link between genes previously associated with ASD and also implicated in
pharmacological therapies commonly used in this population and b) to report the
genotype frequency of genes known to influence drug metabolism among small cohort of
children with ASD. Group of 15 school aged children with ASD were recruited for the
study, venous blood was drawn to analyze the genotype of enzymes implicated in drug
metabolism. Results showed that 66% of our cohort have a mutation to the CYP2C19;
similarly, 72%, 66% and 30% have a mutation in the MTHFR, COMT and OPRM1gene
respectively. The mentioned mutations were associated with ASD and detected as genes
that are involved in drug metabolism as well.
Key Words: Pharmacogenetics, ASD, Genes of ASD.
Key Message: As the number of children with ASD is escalating, the demand for
pharmacological choices is increasing. Thus, it is highly significant to build a treatment
plan for this special population that; interestingly, seems to share a group of genetic
variants that are associated with developing the disorder and implicated in metabolizing a
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group of most commonly prescribed drugs in patients with ASD. Pharmacogenetics is an
evolving test that is highly promising in the future of medicine as it aids in creating an
individualized pharmacological profile, though its use in the clinical settings is still
limited. That profile aims to help healthcare professionals make better treatment choices
especially in patients with chronic diseases and those who are in continuous need for
medications as in children with ASD. That may even enlighten the idea of having genebased treatment plan for gene associated diseases or disorders.
Introduction
Autism Spectrum Disorder (ASD) is a neurodevelopmental disability
characterized by restricted interests and repetitive behaviors and deficits in
communication and social reciprocity skills (White et al., 2007). Due to the prevalence of
children identified with ASD (1 in 68 children), there is a need for interventions targeting
the specific characteristics children and adolescents with ASD display (Center for
Disease Control and Prevention, 2014).
Characteristics of Autism Spectrum Disorder
According to the Diagnostic and Statistical Manual of Mental Disorders (DSMV), there are five factors that make up the diagnostic criteria for ASD (Association,
2013). The first feature includes deficits, which persist over time, in social
communication and social interaction. These deficits can include, but are not limited to,
abnormal social approach, failure to grasp the pragmatics of normal conversation, failure
to start or participate in social interactions, abnormal eye contact and body language,
failure to develop and maintain social relationships, difficulties initiating or maintaining
friendships, and a lack of interest in peers. The second factor includes restricted and
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repetitive behaviors and interests. Examples of this type of behavior include, but are not
limited to, repetitive speech, insistence on adhering to routines, highly restricted
perseverative interests with an abnormal intensity, and unusual sensory interests. The
third factor says that the symptoms must be present in the early developmental period.
The fourth factor says that the symptoms cause clinically significant impairment in
certain areas of functioning. The final factor says that the symptoms are not better
explained by another disability. For the purposes of this research, the focus will be on the
first and second factor relating to the characteristics children with ASD—social and
communication deficits and adherence to perseverative interests (Association, 2013). A
variety of different factors have been implicated in increasing the susceptibility to ASD
incidence, such as the nutritional status (Castro et al., 2016; Schmidt et al., 2011), genetic
variants and the maternal effects whether it is maternal inheritance or prenatal care
including nutrition(Castro et al., 2016; Hettinger et al., 2012).
Medications are one of the multiple interventions used to treat ASD, concomitant
use of multiple therapies was common due to the comorbidity nature of the disease; thus
detecting the efficacy of the treatment was further complicated (Bowker et al., 2011; Zane
et al., 2008). Due to the wide range of adverse effects of pharmacological therapies,
medications are typically one of the most frequently discontinued treatment methods
(Bowker et al., 2011; McPheeters et al., 2011). Therefore, the increasing demands of
pursuing more effective pharmacological therapies to treat ASD, the unclarity of their
efficacy, the alarming adverse effects of drugs commonly prescribed to children diagnosed
with ASD, coupled with the high cost of these modalities, prompts the need for further
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investigation in the field of pharmacological therapies to treat ASD (Bowker et al., 2011;
Zane et al., 2008).
Pharmacogenetics is the study of genes, more specifically variations within
certain genes, which affect the response of the medications in the body. Most of the
identified genetic variations in enzymes, transporters, receptors, and other factors
impacting drug metabolic pathways are a result of single nucleotide polymorphisms (
SNPs), which can ultimately alter the body’s response to that medication (Ensom et al.,
2001). The outcome of these SNPs may range from delayed response, increased toxicity,
extended effect, adverse reaction or drug-drug interactions (Wolf et al., 2000). Thus,
DNA analyzed by the pharmacogenetics testing provides individualized information
about the efficacy and safety of the prescribed medications (McCarthy, 2001).
Wolf et. al., (2000) indicated that 1 in 15 hospital admissions is related to side
effects of the drugs. Therefore, being knowledgeable of the personalized adverse effects
prospectively; by detecting the genetic coding of enzymes responsible for the metabolism
of the prescribed drugs, would reduce the cost, time and harmful events (Bowker et al.,
2011; Zane et al., 2008).
CYP2C19 is highly variable gene tested in pharmacogenetics; more than 80 SNPs
has been related to CYP19. Different alleles were studied in comparison to the wild type
(CYP2C19 *1/*1) that codes for a normal metabolizer. It was found that the
homozygosity of CYP2C19 *17 allele was associated with lower drug concentrations
because of increased enzyme activity. The increase in enzymatic metabolic functions was
mediated by activation of transcription factors that enhance gene transcription of
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CYP2C19 gene. This phenotype variant plays its effect on the metabolism of antidepressants (Hicks et al., 2013; Sim et al., 2006).
CYP2D6 is the most detected gene in the pharmacogenetics testing as it facilitates
in dose control when using psychiatric medications (Wolf et al., 2000). Although this
enzyme present in small quantity in the CYP450 family, its role is highly relevant as it
accounts for metabolizing more than 25% of the most commonly prescribed drugs. In
addition, studying this gene polymorphism is very important as it interferes highly with
the pharmacokinetics of half of the commonly prescribed drugs. Concomitant use of
drugs that inhibit CYP2D6 may lead to inactivation of the gene and predispose the patient
to be a poor metabolizer even though, the patient genotype detected as normal
metabolizer (Hicks et al., 2013; Ingelman-Sundberg, 2005; Mas et al., 2012; Wolf et al.,
2000; S.-F. Zhou, 2009).
COMT gene codes for the COMT enzyme that is found in the liver and brain, it
plays an important role in the degradation of catecholamines neurotransmitters. Decrease
activity of this enzyme cause accumulation of dopamine; increase dopamine
concentration is one of the drug mechanisms used to treat Parkinson disease.
Polymorphism of the COMT gene is the result of the substitution of valine amino acid
with methionine (Val158Met); the outcome is a methionine variant that has lower action
on catalyzing neurotransmitters in the dopaminergic pathway. The increase in dopamine
concentration in methionine variant revealed the causes of response variation for
neurostimulants; such as amphetamine, which is used to treat ADHD. Research showed
that people with valine variant (wild type Val/Val) of the COMT gene tend to have better
drug efficacy to neurostimulant agents as they have lower pre-treatment concentration of
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dopamine in their synapses compared to those with the methionine variant (Bellgrove et
al., 2005; Meyer-Lindenberg et al., 2006; Rakvag et al., 2005).
Analgesics play their role in the body as an agonist at opioid receptors; mu betaendorphin (OPRM1), wide range of variation in response to opioids among patients was
reported. Strong association was found between altered pain threshold and the SNPs G
variant at position 118 (A118G) on the OPRM1 gene. This missense mutation; substitutes
the amino acid asparagine with aspartic, results in decrease glycosylation on the Nterminal site with altered pain sensitivity so dosage modulation of opioids is required
accordingly. Patients who are homozygous to guanine variant (G/G) genotype required
higher doses of morphine compared to those with the normal adenine (A/A) genotype.
However, there are still controversial speculations regarding the heterozygous (A/G)
genotype. Research showed that the fluctuation in opioid response is dependent on the
clinical setting such as labor, cancer, postoperative or chronic disease. Further
investigations highlighted the ethnicity as a potent contributor to this diversity.
Methylenetetrahydrofolate reductase (MTHFR) is the rate-limiting enzyme that
irreversibly convert 5,10 methylenetetrahydrofolates to 5 methylenetetrahydrofolates (5
MTHF) and it is encoded by the MTHFR gene. In order for folate to be in the active form
(5 MTHF), it should go through reduction reaction by the MTHFR enzyme. Folate plays
an important role in the synthesis of nitrogenous bases in DNA and RNA, it is a
coenzyme for 1-carbon transfer in the cysteine cycle that regulates homocysteine levels in
the blood; that being said, a mutation in MTHFR gene; found on chromosome 1 (p36.3),
may lead to impaired DNA repair, DNA hypomethylation, folate deficiency and even an
increase in homocysteine level (Del Greco et al., 2011).
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MTHFR deficiency is associated with increased oxidative and decreased reduced
metabolites in the transculturation pathway of homocysteine, that creates a metabolic
imbalance and increase the risk of oxidative stress which was noticed in autistic children
(James et al., 2006 ). Additionally, MTHFR gene heterozygote mutation has been
strongly associated with hyperhomocysteinemia which predispose to cardiovascular
diseases as it increases the oxidative stress and decreases nitric oxide that has
vasodilatory effects; consequently, MTHFR gene variant underlies an early onset and
increase susceptibility to a hypercoagulable state (James et al., 2006; Kim et al., 2013;
Pramukarso et al., 2015). Folate and B12 vitamin supplementation are administered in
patients who have MTHFR deficiency to reduce the risk of thrombosis (Kim et al., 2013).
Interestingly, these vitamins are also used in the treatment of autism as it improves the
behavioral symptoms; additionally, research showed that prenatal vitamin
supplementation played an important role in preventing autism occurrence in the
offspring (Schmidt et al., 2011). The purpose of this study is two-fold: 1) to investigate
the link between genes previously associated with ASD and also implicated in
pharmacological therapies commonly used in this population and 2) to report the
genotype frequency of genes known to influence drug metabolism among small cohort of
children with ASD.
Methodology
Participants
Participants were recruited from clients participating in the KAP (Kelly Autism
Program) at WKU (Western Kentucky University). Participant characteristics are
displayed in Table 1. In each case, participants and their caregivers were aware of risks
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and requirements for participating made clear that participation is completely voluntary
and will not affect their KAP programming in any way. The testing that was performed in
this study was performed with the best interests of the child in mind. All participants for
this study met the following inclusion criteria:
1. There is documentation that the student has been identified by a third party
professional as having an ASD.
2. The student is between the ages of 7-17
3. The student currently takes a daily medication
As the study sample for this project was composed of minors, there were multiple
steps to the consent process. All caregivers had to complete a written informed consent
indicating requirements for participation, risks involved, and benefits. Four separate
assent documents were created targeting for the unique communication methods of
participants with ASD.
All participants and their caregivers were involved to give utmost consideration
to the unique and specific needs of the participants, who represent a particularly
vulnerable population. This information would be used to obtain child consent.
Caregivers would be asked to identify one of four categories of communication: the child
can: sign his/her name to give consent; check a box to give consent; use sign language to
give consent, or the child can use a communication device to give consent.
Once informed caregiver consent was obtained, one of the investigators or their
designee would acquire participant assent. A total of fifteen (15) participants with ASD
were selected to participate in the study.
Blood Sampling
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The blood draw procedures were coincide with the guidelines set forth by the
U.S. Department of Health and Human Services Office for Human Protections
Research. Blood samples were obtained using Universal Precautions at rest, and
approximately 5 ml of venous blood was drawn.
Genetic Analysis of Blood
All genetic analyses of participants’ blood were conducted at MyGenetx in
Franklin, Tennessee. MyGenetx is a molecular and general chemistry laboratory
involved in research concerning pharmacogenetics.
Results
Genes Frequencies:
All genotypes and phenotypes frequencies for genes that code for major enzymes
systems; CYP450 isoenzymes, involved in drug metabolism are displayed in Table 2.
Additional genes detected in the pharmacogenetics testing, play a role in drug response
were summarized in Table 3 as well.
Medication Stratifications:
Table 4. displays four classes of drug categories that are most commonly
prescribed for children with ASD, showing the percentage from our population that falls
under each drug stratification.
Discussion
Our findings of patients’ sensitivity to some of the medications were related to
mutation in a specific gene. We focused our interest on the medications that are
commonly prescribed for children with ASD, such as anti-depressants, anti-psychotics
and anti-ADHD drugs (Muller, Kekin, Kao, & Brandl, 2013), anti-ADHD drugs were
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used by 30-85% of children with ASD (Dalsgaard et al., 2013; McPheeters et al., 2011).
Methylphenidate which is an anti-ADHD agent was classified as use with caution in
73.3% of the participants; 66.6% are Val/Met variant for the COMT gene and 6.6% are
Met/Met variant, this finding is consistent with other research Froehlich et al. (2011);
McGough et al. (2009) that observed more beneficial role for methylphenidate among
Val/Val variant. The normal function of COMT enzyme; that degrade catecholamines,
decreases the bioavailability of the catecholamines in the synapses, thus Val allele
responds better to neurostimulant medications such as methylphenidate. Val allele
showed more susceptibility to impairment in cognitive functions and exhibit lower
performance in memory tasks as a result of decreased dopamine levels (McGough et al.,
2009; Meyer-Lindenberg et al., 2006). A study by Kereszturi et al. (2008) showed a
significantly higher frequency of the Val/Val allele among ADHD group (28.3%) in
comparison to general population (18.7%), in line with these findings James et al. (2006)
reported (29%) frequency of the homozygous GG genotype in autistic patients. That was
close to the frequency of Val/Val in our sample of 26.6% in children with ASD.
Gadow, Roohi, DeVincent, Kirsch, and Hatchwell (2009) reported that children
with ASD carrying COMT Met158 allele have an increased severity of depression.
Additionally, this mutation tends to be associated with social phobia and tics, as rated by
the teachers of those children.
Another SNP that highly affects the metabolism of drugs was linked to the CYP2C19
gene. Our results showed that the following antidepressants: amitriptyline, clomipramine,
doxepin, imipramine and trimipramine, were classified as the following:
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1) 26.6% of the participants were classified as use with caution since they carry
the 1*/2* or *2/*7 genotypes that have an intermediate CYP2C19 activity. Notably,
Medhasi et al. (2016) detected a higher frequency of 33.2% for the CYP2C19*2 allele
among Thai children with ASD.
2) 46.6% were classified as use alternatives: 40% are CYP2C19 *1/*17 genotype
which is the rapid metabolizer state, 6.6% have the mutated CYP2D6 *4/*5 genotype. To
highlight the significance of the CYP2D6 genotype, the patient who had the mutated
CYP2D6 had nineteen drugs; that are most commonly prescribed for ASD, under the use
with caution category in addition to thirteen drugs under consider alternatives.
Citalopram and escitalopram were classified as consider alternatives in 40% of
patients having the CYP2C19*17 allelic frequency, while sertraline was under the use
with caution category. Our results parallel other studies’ findings since it highlights the
importance of CYP2D6 in metabolizing 25% of all medications and 80% of
antipsychotics and antidepressants, and the importance of CYP2C19 gene in
metabolizing the most commonly prescribed drugs in patients with ASD (Medhasi et al.,
2016). The higher prevalence of having a mutated allele in the CYP2C19 gene among
people with ASD adding to the fact that the same gene is implicated in metabolizing the
most commonly prescribed drugs for this population stress the need for future
investigations in the field.
OPRM1 gene was detected in the pharmacogenetics testing as its mutation causes
alteration in the OPRM1 function leading to change in patients’ response to fentanyl and
hydrocodone; analgesics from the opioid category used postoperatively and in cancer
pain management. Alternatives for hydrocodone should be considered if increasing the
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dose was not sufficient to relief the pain, since the OPRM1 118A>G mutation is
associated with increased risk for hydrocodone adverse effects. Similarly, reduced
response to fentanyl in patients with mutated OPRM1 was observed and close monitoring
during administration of the drug should be ensured as it has a narrow therapeutic index.
From our population 33.3% were carrier for one mutation of OPRM1 gene (OPRM1
A118G AG genotype)
Interestingly, the SNPs of OPRM1 gene was studied as a mutation that does not
only increase pain sensitivity, but also interferes with increased social rejection
sensitivity as well. The similarity in the neuroanatomical and neurochemical factors
associated with physical and social pain, in addition to the fact that G variant carriers
perceive pain differently from those with the A variant, make the OPRM1 gene a good
candidate to be further investigated (Troisi et al., 2012; Way, Taylor, & Eisenberger,
2009). Several research indicate that morphine administration relief distress in infant
animals separated from their mother (Way et al., 2009). Although studies on humans are
still limited, research signify the link between A118G polymorphism of the OPRM1 gene
and fearful of social rejection (Troisi et al., 2012; Way et al., 2009). However, Becker et
al. (2014) study on mice model with OPRM1 gene deletion, detected lack of social
interaction and increase anxiety among other symptoms related to ASD. Thus, the
decreased levels of OPRM1 in early life would negatively impact social reward;
consequently, developing different symptoms related to ASD (Becker et al., 2014).
MTHFR genotype frequency in our population in comparison to other research
that studied autism is displayed in Table 5. The decrease or increase frequency for the AC
or CT and AA respectively, were consistent in our study and in (Marvin Boris & Joseph
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Galanko, 2004). Paradoxically, 1) CC genotype frequency were near the normal range in
our population while it was significantly decreased in (Marvin Boris & Joseph Galanko,
2004), 2) our results showed decrease frequency of the TT genotype whereas the other
study reported significantly higher frequency of the TT genotype in autistic cases. Liu et
al. (2011) results were in line with Marvin Boris and Joseph Galanko (2004) as they
reported higher frequency of the 677TT genotype in people with ASD, suggesting a link
between T allele frequency and ASD. James et al. (2006) signify the role of interaction
between MTHFR gene and RFC gene in increasing the risk for autism.
In comparison to the wild type (1298A>C AA/677C>T CC) of the MTHFR gene,
all the one heterozygotes or compound heterozygotes mutated genotypes are associated
with a decrease in enzyme activity. Although the compromised enzymatic activity for
these mutations is not associated with hyperhomocysteinemia, homozygous TT genotype;
which is also related to ASD, is associated with hyperhomocysteinemia since the
decrease in enzyme activity is around 70%.
Hyperhomocysteinemia is a result of MTFR deficiency, which predisposes to
premature cardiovascular diseases and increases hypercoagulability risks. It is treated
with vitamin B2, B12 and folate supplementation (Kim et al., 2013; Pramukarso et al.,
2015). In the same light, research detected a lack in folate supplementation during
pregnancy in mothers of children with ASD; additionally, folate intake has shown to
improve clinical symptoms of autism and lower homocysteine levels in this population
(Castro et al., 2016; Schmidt et al., 2011). Research investigating the interaction between
the genetic and nutritional factors in respect to their association with behavioral and
clinical symptoms in children with ASD is still not well established

53

Overall, this research study adds to the small literature base of pharmacogenetics
and people with ASD. Although, the sample size for this study is relatively small, the
consistency of our findings, regarding the prevalence of genotype frequency in ASD
population, with other research make it a very relevant information that aim to create a
genetic classification for genetic disorders. The main focus of the paper is to relate the
genotype frequency with the clinical relevance in ASD children in order to provide better
medical care for this special population.
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Chapter Six: Tables
Table 1. Participant Demographics
Number

15

Age

7-17 yrs.

Race

14 Caucasian / 1 Hispanic

Gender

12 Male / 3 Female
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Table 2. Genotype frequencies for CYP450 family of enzymes
Gene

Genotype

Phenotype

Participants n(%)

CYP1A2

*1A/*1F
*1F/*1F
*1A/*1A

Normal Metabolizer- High inducibility
Normal Metabolizer- Possible inducibility

14(93%)
1(6.6%)

CYP2B6

*1/*1

Normal Metabolizer

10(66%)

*1/*6

Intermediate Metabolizer

4(26.6%)

*6/*6

Low Metabolizer

1(6.6%)

*1/*1

Normal Metabolizer

5(33.3%)

*1/*17

Rapid Metabolizer

6(40%)

*1/*2
*2/*17

Intermediate Metabolizer

4(26.6%)

*1/*9
*1/*1
*2/*41
*2/*5/*35
*2/*4
*1/*2
*2/*5
*1/*35
*4/*5

Normal Metabolizer
Poor Metabolizer

14(93.3%)
1(6.6%)

*1/*1

Normal Metabolizer

13(68%)

*3/*22

Intermediate Metabolizer

2(13.3%)

*1/*3

Intermediate Metabolizer

4(26.6%)

*3/*3

Poor metabolizer

11(73.3%)

CYP2C19

CYP2D6

CYP3A4

CYP3A5
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Table 3. Genotype frequencies for enzymes implicated in drug response in the body

Gene

Genotype

Phenotype

Paricipants n(%)

ANKK1/DRD2

DRD2:Taq1A GG

Unaltered DRD2 function

9( 60%)

DRD2:Taq1A AG

Altered DRD2 function

5(33%)

DRD2:Taq1A AA

Altered DRD2 function

1(6.6%)

Val158Met GG

High/Normal COMT activity

4(26.6%)

Val158Met AG

Intermediate COMT activity

10(66.6%)

Val158Met AA

Low COMT activity

1(6.6%)

A118G AA

Normal OPMR1 Function

10(66.6%)

A118G AG

Altered OPMR1 Function

5(33.3%)

521T>C TT

Normal Transporter Function

9(60%)

521T>C TC

Intermediate Transporter Function

6(40%)

1298A>C AA
677C>T CC

Wild Type / Normal MTHFR Activity

4(26.6%)

1298A>C AA
677C>T CT

One heterozygote mutation(60% of
normal enzyme activity)

5(33.3%)

1298A>C AC
677C>T CC

One heterozygote mutation(80% of
normal enzyme activity)

3(20%)

1298A>C AC
677C>T CT

Compound heterozygote mutation
(reduced enzyme activity)

2(13.3%)

1298A>C AA
677C>T TT

Two C677T mutation (homozygous) 30%
of normal activity

1(6.6%)

COMT

OPRM1

SLCO1B1

MTHFR

Table 4. Drug stratification of the most commonly prescribed medications for ASD
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Anti- ADHD
Amphetamine (Adderall)
Atomoxetine (Strattera)
Clonidine (Kapvay)
Dextroamphetamine
(Dexedrine)
Guanfacine (Intuniv)
Lisdexamfetammine (Vyvanse)
Dexmethylphenidate (Focalin)
Mehtylphenidate (Ritalin)

Standard
Precautions
14 (93.3%)
14 (93.3%)
15 (100%)

Use With
Caution
1 (6.6%)
1 (6.6%)

14 (93.3%)

1 (6.6%)

15 (100%)
14 (93.3%)
4 (26.6%)
4 (26.6%)

1 (6.6%)
11 (73.3%)
11 (73.3%)

Antiaddictives
Bupropion (Wellbutrin, Zyban, Aplenzin,
Contrave)
Naltrexone (Vivitrol)

Antidepressants
Amoxapine (Amoxapine)
Citalopram (Celexa)
Desipramine (Norpramin)
Desvenlafaxine (Pristiq)
Duloxetine (Cymbalta)
Escitalopram (Lexapro)
Fluoxetine (Prozac,
Sarafem)
Fluvoxamine (Luvox)
Levomilnacipran (Fetzima)
Maprotiline (Ludiomil)
Mirtazapine (Remeron)
Nefazodone (Serzone)
Nortriptyline (Pamelor)
Paroxetine (Paxil, Brisdelle)
Protriptyline (Vivactil)
Sertraline (Zoloft)
Venlafaxine (Effexor)
Vilazodone (Viibryd)
Vortioxetine (Brintellix)

Standard
Precautions

Use With
Caution

7 (46.6%)

8 (53.3%)

5 (33.3%)

10 (66.6%)

Standard
Precautions
14 (93.3%)
9 (60%)
14 (93.3%)
15 (100%)
14 (93.3%)
9 (60%)

Use With
Caution
1 (6.6%)

Consider
Alternatives

Consider
Alternatives

Consider
Alternatives
6 (40%)
1 (6.6%)

1 (6.6%)
6 (40%)

15 (100%)
14 (93.3%)
15 (100%)
14 (93.3%)
15 (100%)
14 (93.3%)
14 (93.3%)
14 (93.3%)
14 (93.3%)
9 (60%)
14 (93.3%)
15 (100%)
14 (93.3%)

1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
1 (6.6%)
6 (40%)
1 (6.6%)
1 (6.6%)
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Amitriptyline (Elavil)
Clomipramine (Anafranil)
Doxepin (Silenor)
Imipramine (Tofranil)
Trimipramine (Surmontil)

Antipsychotics
Aripiprazole (Abilify)
Asenapine (Saphris)
Brexpiprazole (Rexulti)
Chlorpromazine
(Thorazine)
Fluphenazine (Prolixin)
Haloperidol (Haldol)
Iloperidone (Fanapt)
Lurasidone (Latuda)
Paliperidone (Invega)
Perphenazine (Trilafon)
Pimozide (Orap)
Quetiapine (Seroquel)
Risperidone (Risperdal)
Thioridazine (Mellaril)
Thiothiexene (Navane)
Trazodone (Oleptro)
Trifluoperazine (Stelazine)
Ziprasidone (Geodon)
Clozapine (Clozaril)
Olanzapine (Zyprexa)
Tetrabenazine (Xenazine)

4 (26.6%)
4 (26.6%)
4 (26.6%)
4 (26.6%)
4 (26.6%)

4 (26.6%)
4 (26.6%)
4 (26.6%)
4 (26.6%)
4 (26.6%)

Standard
Precautions

Use With
Caution

14(93.3%)

1 (6.6%)

14(93.3%)

1 (6.6%)

14(93.3%)

1 (6.6%)

14(93.3%)
14(93.3%)
14(93.3%)

1 (6.6%)

14(93.3%)
14(93.3%)

1 (6.6%)
1 (6.6%)

7 (46.6%)
7 (46.6%)
7 (46.6%)
7 (46.6%)
7 (46.6%)

Consider
Alternatives

1 (6.6%)
1 (6.6%)

14(93.3%)
14(93.3%)
15 (100%)
15 (100%)
15 (100%)
15 (100%)
1 (6.6%)
1 (6.6%)

1 (6.6%)
1 (6.6%)

14(93.3%)
14(93.3%)
15 (100%)
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Table 5. Comparison of MTHFR genotype frequency between our sample and Marvin
Boris and Joseph Galanko (2004)

Genotype
TT
CT
AA
AC
CC

Marvin Boris and
Joseph Galanko
(2004)
Autistic
Control
Our results
23%
11%
6.60%
56%
41%
46.60%
55%
44%
66.60%
39%
47%
33.30%
21%
48%
46.60%
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Chapter Eight: Appendix
APPENDIX A
INFORMATIONAL SHEET

Do you have a child with Autism Spectrum Disorder (ASD) who has difficulty
sleeping? If so, your child may be eligible to participate in an innovative genetic mapping
study.
Western Kentucky University is partnering with MyGenetx to conduct genetic
mapping of students with ASD and sleep difficulties
If you are interested in participating, please read and fill out the attached consent
document
If you participate, MyGentex will give you a drug panel that highlights medicines
that may be most effective for your child (value of ~$400), a $25 gift card to a local
business, AND you can say you helped moved forward the scientific knowledge of ASD.
An open forum question and answer session will be scheduled for anyone
interested in learning more about this.
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APPENDIX B
CAREGIVER INFORMED CONSENT DOCUMENT

You are being asked to participate in a project conducted through Western
Kentucky University. The University requires that you give your signed agreement to
participate in this project.

The investigator is available to discuss with you in detail the purpose of the
project, the procedures to be used, and the potential benefits and possible risks of
participation. You may ask him any questions you have to help you understand the
project. A basic explanation of the project is written below. Please read this explanation
and discuss with the investigator any questions you may have.
If you then decide to participate in the project, please sign on the last page of this
form. You will be given a copy of this form to keep.

1. Nature and Purpose of the Project: The purpose of this study is to investigate
a possible genetic link between sleep disturbance and Autism Spectrum
Disorders (ASD). Prior research in this area suggests there is a genetic link
between ASD and sleep disorders. By identifying the genes involved we can
identify the most appropriate treatments to improve the lives of those with
ASD and their families. Information from this study will also add to the
research towards determining the root cause of ASD.

67

2.

Explanation of Procedures:

To be included in the study, your child must meet the following inclusion criteria:


There is documentation that your child has been identified by a third party
professional as having an Autism Spectrum Disorder.



You have identified that your child currently has or has had in the past
disturbed sleep



Your child is between 7-17 years of age



Your child is currently on a daily medication

If your child does not meet one of these criteria, he/she will not be included in this
study and we will notify you via a letter and/or phone call. Also, we will randomly select
participants who meet the inclusion criteria if more than 15 participants sign up. We will
notify you via a letter and/or phone call if your child has been selected to participate. If
your child is chosen to participate, we will conduct the blood draw at the Suzanne Vitale
Clinical Education Complex (SVCEC). All blood draws will be done by a skilled
professional trained in phlebotomy from the Exercise Physiology laboratory in the School
of Kinesiology, Recreation & Sport (KRS). Also, a professional trained in ASD will be
present to help with the blood draw. Blood samples will be obtained using Universal
Precautions at rest. Blood draw procedures are as follows:
1. Wrap a tourniquet around your child’s upper arm to stop blood flow.
2. Sterilize the puncture site with alcohol.
3. Insert the needle into the vein
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4. Attach the appropriate test tube to the needle. Allow the blood to fill the test
tube.
5. Remove the tourniquet to restore blood flow.
6. Place a gauze pad over the site while withdrawing the needle.
7. Apply firm pressure to the site until bleeding has stopped.

An individual vial of your child’s blood will be immediately de-identified to
ensure confidentiality. It will be stored in the KRS Exercise Physiology laboratory until it
is shipped to MyGenetx in Franklin, Tennessee for genetic analysis. Shipping will be
done via United Parcel Service. All genetic analyses of participants’ blood will be
conducted at MyGenetx in Franklin, Tennessee. MyGenetx is a molecular and general
chemistry laboratory involved in research.
1. Discomfort and Risks: Venipuncture blood collection can cause minor
bruising around the sample area and slight discomfort during the sampling
procedure. Nausea and fainting can occur. There is a slight risk in the
increase in the potential for problem behaviors that may be associated with a
blood draw, such as aggression, property destruction or self-injury. If at any
time any problem behaviors occur during the blood draw, the procedures will
be immediately stopped. Although we will take multiple precautionary steps
to protect and safeguard confidentiality, with the transport of data, there is
still a very small chance that confidentiality will be breached.
2. Benefits: If you participate in this study, you will be given an individual
pharmacogenetics (PGx) report for your child (a $400 - $500 value). The PGx
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is a detailed analysis of the effectiveness of prescription drugs based on
individual genetics. It will detail which drugs your child metabolizes more
effectively than others and can improve treatment.
3. You will also receive a gift card to a local store valued at $25. This gift card
will be given to compensate for time travel expenses associated with
participating in this study.
4. Finally, the results of this study will potentially allow researchers to identify
the underlying genetic components of ASD. This can result in more targeted
interventions and prevention efforts. This information will be valuable to all
people affected by ASD.
5. Confidentiality: Your child’s blood will be numerically coded for anonymity
and stored in a locked office at KRS Exercise Physiology laboratory and in a
locked office at MyGentex in Franklin, TN. Any data collected from the
blood sample will be kept in a password-protected document on a passwordprotected computer in the investigator’s office. Any data collected and
recorded on hard copy will also be locked and stored in the same location.
The data will be kept secure for a minimum of three years after project
completion.
6. Refusal/Withdrawal: Refusal to participate in this study will have no effect
on any future services you may be entitled to from the University or with the
Kelly Autism Program. You are free to withdraw from the study at any time
with no penalty.
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You understand also that it is not possible to identify all potential risks in
an experimental procedure, and you believe that reasonable safeguards have
been taken to minimize both the known and potential but unknown risks.

__________________________________________

_______________

Signature of Caregiver

Date

__________________________________________
_____________________
Signature of Caregiver

Date
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APPENDIX C
LETTER TO PARENTS TO DETERMINE COMMUNICATION STYLE
AND POTENTIAL BEHAVIORAL PROCEDURES FOR THE BLOOD DRAW

Dear family members and/or legal guardians,

Thank you for agreeing to participate in this study. We will ask your child if
he/she wants to participate in the study. We will ask your child using his/her best method
of communication. Please check the box next to the method that your child is most likely
to communicate whether he/she wants to be in the study.

____ My child is verbal and can sign his/her name to show whether he/she wants
to be in the study.

____ My child is verbal and can check a box to show whether he/she wants to be
in the study.

____ My child uses sign language and will sign whether he/she wants to be in the
study.

___ My child uses a communication device and will use this to shoe whether
he/she wants to be in the study.
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Also, AutismSpeaks has published a guide to drawing blood with children with
ASD. They recommend certain supports to help the blood draw go smoothly. We are
happy to put in place any additional supports your child may need. If you are interested
in any of the supports, please contact the head of this study. Some examples of supports
that can you request are:


Relaxation techniques



First/Then boards



Visual schedules



Reinforcers



Please list other supports you think may be necessary:

If there are other supports you would like, please let us know and we will
try our best to put those in place.
Sincerely,
__________________________________________
___________________
Participant’s name

Date:

__________________________________________
Caregiver name
__________________________________________
Caregiver signature
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APPENDIX D
INFORMED ASSENT DOCUMENT
FOR RESEARCH INVOLVING MINORS

Informed Consent Document for Participants who use Communication
Devices

This script should be read to the potential participants. Do not change the
wording in any way. After you have read the script, ask the participant to use a
communication device to state “yes” or “no.”

Your parents have said it is okay for me to ask you if you want to be part of this
project. Scientists at Western Kentucky University are looking at genes and autism. As
part of the project, the scientists will draw your blood one time. They will also draw
blood from 14 other students in Kentucky with autism. They will send all of the blood to
a lab in another state. After we draw your blood, we will not know which blood is yours.
It will go into a big computer system that will look for ways that the children with autism
are similar to one another. Knowing this about children with autism will help scientists
better know about autism. If you do not want to do this, it is okay with your parents and
it is okay with us. If you say you will do it, but think later that you do not, just tell
someone you do not want to do it and it will be okay.
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Use your ipad (communication device) to tell me if you want to be in this project.
Say yes, if you want to be in the study and let the scientists draw your blood. Say no if
you do not want to be in the study or let scientists draw your blood.

The adult obtaining informed consent should mark on the boxes below whether
the student would like to participate and sign and date the document.

_______ I do want to participate in the study

_______ I do not want to participate in the study

________________________________________
_________________
Participant signature (if applicable)

Date

________________________________________
__________________
Signature of the adult obtaining consent
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Date

APPENDIX E
INFORMED ASSENT DOCUMENT
FOR RESEARCH INVOLVING MINORS
Informed Consent Document for Participants who Sign their Names

This script should be read to the potential participants. Do not change the
wording in any way. After you have read the script, ask the participant to check a box
and sign his/her name if he/she wants to participate in the study.

Your parents have said it is okay for me to ask you if you want to be part of this
project. Scientists at Western Kentucky University are looking at genes and autism. As
part of the project, the scientists will draw your blood one time. They will also draw
blood from 14 other students in Kentucky with autism. They will send all of the blood to
a lab in another state. After we draw your blood, we will not know which blood is yours.
It will go into a big computer system that will look for ways that the children with autism
are similar to one another. Knowing this about children with autism will help scientists
better know about autism. If you do not want to do this, it is okay with your parents and
it is okay with us. If you say you will do it, but think later that you do not, just tell
someone you do not want to do it and it will be okay.

I will pass you this paper and you will put an X next to whether you want to be in
this study. If you do, then put an X next to “yes.” If you do not, put an X next to “no.”
Then, at the bottom, sign your name and put the date.
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Pass the paper to the participant. The adult obtaining consent should then sign
and date the paper.

_______ Yes! I do want to participate in the study

_______ No. I do not want to participate in the study

________________________________________
_________________
Participant signature (if applicable)

Date

________________________________________
__________________
Signature of the adult obtaining consent
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Date

APPENDIX F
INFORMED ASSENT DOCUMENT
FOR RESEARCH INVOLVING MINORS

Informed Consent Document for Participants who Check a Box

This script should be read to the potential participants. Do not change the
wording in any way. After you have read the script, ask the participant to check a box.

Your parents have said it is okay for me to ask you if you want to be part of this
project. Scientists at Western Kentucky University are looking at genes and autism. As
part of the project, the scientists will draw your blood one time. They will also draw
blood from 14 other students in Kentucky with autism. They will send all of the blood to
a lab in another state. After we draw your blood, we will not know which blood is yours.
It will go into a big computer system that will look for ways that the children with autism
are similar to one another. Knowing this about children with autism will help scientists
better know about autism. If you do not want to do this, it is okay with your parents and
it is okay with us. If you say you will do it, but think later that you do not, just tell
someone you do not want to do it and it will be okay.
I will pass you this paper and you will put an X next to whether you want to be in
this study. If you do, then put an X next to “yes.” If you do not, put an X next to “no.”
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Pass the paper to the participant. The adult obtaining consent should then
sign and date the paper.

_______ Yes! I do want to participate in the study

_______ No. I do not want to participate in the study

________________________________________
_________________
Participant signature (if applicable)

Date

________________________________________
__________________
Signature of the adult obtaining consent
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Date

APPENDIX G
INFORMED ASSENT DOCUMENT
FOR RESEARCH INVOLVING MINORS
Informed Consent Document for Participants who use Sign Language

This script should be read to the potential participants. Do not change the
wording in any way. After you have read the script, ask the participant to use sign
language to show their willingness to participate. Then you sign the paper to show you
have followed these guidelines.

Your parents have said it is okay for me to ask you if you want to be part of this
project. Scientists at Western Kentucky University are looking at genes and autism. As
part of the project, the scientists will draw your blood one time. They will also draw
blood from 14 other students in Kentucky with autism. They will send all of the blood to
a lab in another state. After we draw your blood, we will not know which blood is yours.
It will go into a big computer system that will look for ways that the children with autism
are similar to one another. Knowing this about children with autism will help scientists
better know about autism. If you do not want to do this, it is okay with your parents and
it is okay with us. If you say you will do it, but think later that you do not, just tell
someone you do not want to do it and it will be okay.
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Use your signs to tell me if you want to be in this project. Show me yes, if you
want to be in the study and let the scientists draw your blood. Show me no if you do not
want to be in the study or let scientists draw your blood.

Pass the paper to the participant. The adult obtaining consent should then sign
and date the paper.

_______ Yes! I do want to participate in the study

_______ No. I do not want to participate in the study

________________________________________
_________________
Participant signature (if applicable)

Date

________________________________________
__________________
Signature of the adult obtaining consent
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Date

APPENDIX H
Survey
The purpose of this survey is to get your personal opinion about some important
issues related to pharmacogenomic testing. Please answer all these questions as honestly
as you can. All your answers will be completely confidential. If for any reason, you do
not feel comfortable answering any specific question, you can decline answering it by not
marking an answer choice.
Key definitions:
Pharmacogenetics: Pharmacogenetics is the study of how individuals’ genetic
make-up (genes in their DNA) interacts with medication. Although medications are
meant to work the same way, medications affect people differently because of their
genes.
Pharmacogenomic test: A test (e.g. blood test) to investigate peoples’ genetic
make-up (genes in their DNA), in order to find out how the individual metabolizes the
medication, and therefor, how well a medication will work for that individual.
1.

How much have you heard about pharmacogenetics? (Through media, friends,
peers, etc.)
a.
Nothing
b.
A little bit
c.
A fair amount
d.
A lot

2.

How familiar are you with pharmacogenetics?
a.
Extremely familiar
b.
Very familiar
c.
Moderately familiar
d.
Slightly familiar
e.
Not at all familiar

3.

How would you rate the importance of pharmacogenetics testing?
a.
Extremely important
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b.
c.
d.
e.

Very important
Moderately important
Slightly important
Not at all important

4.

How would you rate the benefit of pharmacogenetics testing?
a.
Extremely beneficial
b.
Very beneficial
c.
Moderately beneficial
d.
Slightly beneficial
e.
Not at all beneficial

5.

How likely are you to talk to your doctor about pharmacogenetics?
a.
Extremely likely
b.
Very likely
c.
Moderately likely
d.
Slightly likely
e.
Not at all likely

6.

Learning about how my body metabolizes medications could make my
medications safer and more effective
a.
Strongly agree
b.
Somewhat agree
c.
Neither agree nor disagree
d.
Somewhat disagree
e.
Strongly disagree

7.

I would benefit from learning about how specific genes in the body can affect the
metabolism of medication.
a.
Strongly agree
b.
Somewhat agree
c.
Neither agree nor disagree
d.
Somewhat disagree
e.
Strongly disagree

8.

I would ask my doctor to use pharmacogenetics results to determine the best
drug for me.
a.
Strongly agree
b.
Somewhat agree
c.
Neither agree nor disagree
d.
Somewhat disagree
e.
Strongly disagree

9.

I have a good understanding of the healthcare application of pharmacogenetics.
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a.
b.
c.
d.
e.

Strongly agree
Somewhat agree
Neither agree nor disagree
Somewhat disagree
Strongly disagree

10.

I would request a pharmacogenetics test to determine my best choice of medicine
in the future.
a.
Strongly agree
b.
Somewhat agree
c.
Neither agree nor disagree
d.
Somewhat disagree
e.
Strongly disagree

11.

Have you ever experienced a side effect (bad reaction) from a medication?
a.
Yes
b.
No
c.
Don’t know
d.
I have never taken any medications

12.

Have you ever found that a medication did not work for you?
a.
Yes
b.
No
c.
Don’t know
d.
I have never taken any medications

13.

How interested are you in doing more pharmacogenetics testing?
a.
Extremely interested
b.
Very interested
c.
Moderately interested
d.
Slightly interested
e.
Not at all interested

14.

How comfortable are you talking to your doctor about pharmacogenetics?
a.
Extremely comfortable
b.
Very comfortable
c.
Moderately comfortable
d.
Slightly comfortable
e.
Not at all comfortable

15.

How comfortable are you talking to your child’s doctor about pharmacogenetics?
a.
Extremely comfortable
b.
Very comfortable
c.
Moderately comfortable
d.
Slightly comfortable
e.
Not at all comfortable
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16.

I would ask my child’s doctor to use my child's pharmacogenetics results to
determine the best medication for them.
a.
Strongly agree
b.
Somewhat agree
c.
Neither agree nor disagree
d.
Somewhat disagree
e.
Strongly disagree

17.

Has your child ever experienced a side effect (bad reaction) from a medication?
a.
Yes
b.
No
c.
Don’t know

18.

Have you ever found that a medication did not work for your child?
a.
Yes
b.
No
c.
Don’t know

19.

I was hesitant to have my child participate in the research study because it
involved genetic analysis.
a.
Strongly agree
b.
Somewhat agree
c.
Neither agree nor disagree
d.
Somewhat disagree
e.
Strongly disagree

20. Do you have anything else that you would like to share about your opinions
concerning pharmacogenetics?
___________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________

21. I agree to contact me for a 7 day period follow up through e-mail
a. Yes
b. No
If yes, please provide your e-mail address below
___________________________________________________________
_______________
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APPENDIX I
Oral Presentation of the Training Session
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